Ernest A Kopecky
Overview
Explore the profile of Ernest A Kopecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleykamp B, Dworkin R, Turk D, Bhagwagar Z, Cowan P, Eccleston C, et al.
Pain
. 2021 Sep;
163(6):1006-1018.
PMID: 34510135
Chronic pain clinical trials have historically assessed benefit and risk outcomes separately. However, a growing body of research suggests that a composite metric that accounts for benefit and risk in...
2.
Gewandter J, Dworkin R, Turk D, Farrar J, Fillingim R, Gilron I, et al.
Pain Rep
. 2021 May;
6(1):e895.
PMID: 33981929
Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive...
3.
Smith S, Dworkin R, Turk D, McDermott M, Eccleston C, Farrar J, et al.
Pain
. 2020 Jun;
161(11):2446-2461.
PMID: 32520773
Interpreting randomized clinical trials (RCTs) is crucial to making decisions regarding the use of analgesic treatments in clinical practice. In this article, we report on an Initiative on Methods, Measurement,...
4.
Gewandter J, Dworkin R, Turk D, Devine E, Hewitt D, Jensen M, et al.
J Pain
. 2019 Dec;
21(9-10):931-942.
PMID: 31843583
The estimated probability of progressing from phase 3 analgesic clinical trials to regulatory approval is approximately 57%, suggesting that a considerable number of treatments with phase 2 trial results deemed...
5.
Meske D, Vaughn B, Kopecky E, Katz N
J Pain Res
. 2019 Dec;
12:3161-3165.
PMID: 31819600
Background: Many aspects of study conduct impact the observed effect size of treatment. Data were utilized from a recently published meta-analysis of randomized, double-blind, placebo-controlled, clinical trials performed for the...
6.
Kopecky E
Clin J Pain
. 2019 Apr;
35(6):481-486.
PMID: 30985400
Aims/objectives/background: Children represent a patient demographic composed of multiple, unique subpopulations differentiated by rapidly changing age-related physiology, which includes the means of metabolizing opioids. Opioids are an important part of...
7.
Meske D, Kopecky E, Passik S, Shram M
J Opioid Manag
. 2018 Nov;
14(5):359-372.
PMID: 30387859
Objective: To further characterize the human abuse potential and pharmacokinetics (PK) of Oxycodone DETERx (Xtampza® ER) after intact and chewed oral administration. Design: Randomized, double-blind, triple-dummy, active- and placebo-controlled, single-dose,...
8.
Markman J, Meske D, Kopecky E, Vaughn B, OConnor M, Passik S
J Pain Res
. 2018 Oct;
11:2051-2059.
PMID: 30288095
Objectives: This post hoc analysis of data from a randomized, double-blind, placebo-controlled, enriched-enrollment randomized-withdrawal Phase III study evaluated the safety, tolerability, and analgesic efficacy of Oxycodone DETERx extended-release (ER), abuse-deterrent...
9.
Brennan M, Kopecky E, Marseilles A, OConnor M, Fleming A
Pain Manag
. 2017 Nov;
7(6):461-472.
PMID: 29171358
Aim: To further characterize the pharmacokinetics of Xtampza ER. Subjects & Methods: This was an open-label, randomized, active-controlled, five-treatment, five-period, naltrexone-blocked, cross-over study. Healthy subjects received five equivalent oxycodone doses:...
10.
Walco G, Kopecky E, Weisman S, Stinson J, Stevens B, Desjardins P, et al.
Pain
. 2017 Nov;
159(2):193-205.
PMID: 29140927
Clinical trials to test the safety and efficacy of analgesics across all pediatric age cohorts are needed to avoid inappropriate extrapolation of adult data to children. However, the selection of...